First European Conference on SRS/SBRT and IG-IMRT Held in Milan
First European Conference on SRS/SBRT and IG-IMRT Held in Milan
AsiaNet 52293
SUNNYVALE, California, 4 Mar. 2013 /PRN=KYODO JBN/ --
Accuray Incorporated [http://www.accuray.com/ ] (Nasdaq: ARAY
[http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=ARAY ]), today
announced highlights from the First European Conference on stereotactic
radiosurgery/stereotactic body radiation therapy (SRS/SBRT) and image-guided
intensity-modulated radiation therapy (IG-IMRT), hosted in partnership with the
Istituto Europeo di Oncologia Milano and the Universita degli studi di Milano,
held in Milan, Italy on February 22-23, 2013.
The conference "Radiation Oncology: can we still treat without image
guidance?" was attended by more than 400 healthcare professionals, including
radiation oncologists, medical physicists and hospital administrators from 32
countries. Outcomes of recent research in areas such as central nervous system
(CNS), head and neck, breast, lung, gastrointestinal (GI), pelvis, total marrow
irradiation (TMI) and pediatrics were presented.
The independent Scientific Committee, led by Prof. Roberto Orecchia
(Istituto Europeo di Oncologia Milano, Italy) and Prof. Eric Lartigau (Centre
Oscar Lambret, Lille, France), focused on new developments in the field and
developed an educational event to discuss the need of image guidance for a
variety of clinical indications in modern radiation therapy. "Daily image
guidance is crucial for all high-precision treatments, also for palliative
treatments" said Prof. Eric Lartigau.
"The TomoTherapy(R) System provides an automatic process that makes our
daily work easy" said Prof. Dirk Verellen, UZ Brussel.
Prof. Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of Rotterdam,
said "Additionally, dose to the healthy tissue can be strongly reduced using
optimal and numerous non-coplanar beams when treating prostate cancer"
comparing non-coplanar treatments to coplanar treatments.
"There are non-adaptive and real-time adaptive solutions, but the only
solution that adapts for target motion in real-time, available clinically, is
the CyberKnife(R) System", added Dr. Iciar Santa Olalla.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.
Safe Harbor Statement Statements made in this press release that are not
statements of historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release relate, but are not
limited, to clinical applications, clinical results, patient outcomes, and the
Company's leadership position in radiation oncology innovation. Forward-looking
statements are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including risks detailed from
time to time under the heading "Risk Factors" in the company's report on Form
10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on
November 8, 2012 & February 6, 2013, and as updated periodically by our other
filings. Forward-looking statements speak only as of the date the statements
are made and are based on information available to the Company at the time
those statements are made and/or management's good faith belief as of that time
with respect to future events. The Company assumes no obligation to update
forward-looking statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking information,
except to the extent required by applicable securities laws. Accordingly,
investors should not place undue reliance on any forward-looking statements.
Contacts
Anja Kleber
Marketing Director
Tel +33(0)1-55-23-20-20
akleber@accuray.com
Sophie Baumont
Edelman Paris
Tel +33(0)1-56-69-75-94
sophie.baumont@edelman.com
SOURCE: Accuray Incorporated
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。